Gain-of-function p53R175H blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma

被引:3
|
作者
Haagsma, Jacob [1 ,2 ]
Kolendowski, Bart [1 ]
Buensuceso, Adrian [1 ,2 ]
Valdes, Yudith Ramos [1 ]
DiMattia, Gabriel E. [1 ,3 ,4 ]
Shepherd, Trevor G. [1 ,2 ,3 ,5 ,6 ]
机构
[1] London Reg Canc Program, Mary & John Knight Translat Ovarian Canc Res Unit, London, ON, Canada
[2] Western Univ, Schulich Sch Med & Dent, Dept Anat & Cell Biol, London, ON, Canada
[3] Western Univ, Schulich Sch Med & Dent, Dept Oncol, London, ON, Canada
[4] Western Univ, Schulich Sch Med & Dent, Dept Biochem, London, ON, Canada
[5] Western Univ, Schulich Sch Med & Dent, Dept Obstet & Gynaecol, London, ON, Canada
[6] London Reg Canc Program, 790 Commissioners Rd East,Room A4-836, London, ON N6A 4L6, Canada
基金
加拿大健康研究院;
关键词
P53; MUTANTS; WILD-TYPE; CANCER; P73; MUTATIONS; SURVIVAL; TP53; GENE; P63; DISRUPTION;
D O I
10.1038/s41598-023-38609-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Ovarian high-grade serous carcinoma (HGSC) is a highly lethal malignancy for which early detection is a challenge and treatment of late-stage disease is ineffective. HGSC initiation involves exfoliation of fallopian tube epithelial (FTE) cells which form multicellular clusters called spheroids that colonize and invade the ovary. HGSC contains universal mutation of the tumour suppressor gene TP53. However, not all TP53 mutations are the same, as specific p53 missense mutants contain gain-of-function (GOF) properties that drive tumour formation. Additionally, the role of GOF p53 in spheroid-mediated spread is poorly understood. In this study, we developed and characterized an in vitro model of HGSC based on mutation of TP53 in mouse oviductal epithelial cells (OVE). We discovered increased bulk spheroid survival and increased anchorage-independent growth in OVE cells expressing the missense mutant p53(R175H) compared to OVE parental and Trp53ko cells. Transcriptomic analysis on spheroids identified decreased apoptosis signaling due to p53(R175H). Further assessment of the apoptosis pathway demonstrated decreased expression of intrinsic and extrinsic apoptosis signaling molecules due to Trp53 deletion and p53(R175H), but Caspase-3 activation was only decreased in spheroids with p53(R175H). These results highlight this model as a useful tool for discovering early HGSC transformation mechanisms and uncover a potential anti-apoptosis GOF mechanism of p53(R175H).
引用
收藏
页数:14
相关论文
共 50 条
  • [21] p16 as a prognostic indicator in ovarian/tubal high-grade serous carcinoma
    Beirne, James P.
    McArt, Darragh G.
    James, Jacqueline A.
    Salto-Tellez, Manuel
    Maxwell, Perry
    McCluggage, W. Glenn
    HISTOPATHOLOGY, 2016, 68 (04) : 615 - 618
  • [22] Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers
    Bischof, Katharina
    Knappskog, Stian
    Hjelle, Sigrun M.
    Stefansson, Ingunn
    Woie, Kathrine
    Salvesen, Helga B.
    Gjertsen, Bjorn T.
    Bjorge, Line
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [23] Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers
    Katharina Bischof
    Stian Knappskog
    Sigrun M. Hjelle
    Ingunn Stefansson
    Kathrine Woie
    Helga B. Salvesen
    Bjorn T. Gjertsen
    Line Bjorge
    Scientific Reports, 9
  • [24] p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer
    Park, Eunhyang
    Han, Hyunho
    Choi, Sung-Eun
    Park, Hyunjin
    Woo, Ha-Young
    Jang, Mi
    Shim, Hyo-Sup
    Hwang, Sohyun
    Kang, Haeyoun
    Cho, Nam-Hoon
    DIAGNOSTICS, 2022, 12 (03)
  • [25] MYC is sufficient to generate mid-life high-grade serous ovarian and serous endometrial carcinomas in a BRCA wild type p53-R270H mouse model
    Blackman, Alexandra
    Rees, Amy
    Bowers, Rob
    Jones, Christian
    Vaena, Silvia
    Carter, Shelby
    Villamor, Evan
    Evans, Della
    Fullbright, George
    Long, David
    Spruill, Laura
    Romeo, Martin
    Helke, Kristi
    Emanuel, Anthony
    Delaney, Joe
    CLINICAL CANCER RESEARCH, 2024, 30 (05)
  • [26] Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma
    Qiu, Chunping
    Wang, Yu
    Wang, Xiao
    Zhang, Qing
    Li, Yinuo
    Xu, Ying
    Jin, Chengjuan
    Bu, Hualei
    Zheng, Wenxin
    Yang, Xingsheng
    Lu, Nan
    Kong, Beihua
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (06) : 2041 - 2050
  • [27] Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
    Kasherman, Lawrence
    Garg, Swati
    Tchrakian, Nairi
    Clarke, Blaise
    Karakasis, Katherine
    Kim, Raymond H.
    Stockley, Tracy L.
    Dhani, Neesha
    Oza, Amit M.
    Lheureux, Stephanie
    GYNECOLOGIC ONCOLOGY REPORTS, 2021, 36
  • [28] Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer
    Hayano, Takahide
    Yokota, Yuki
    Hosomichi, Kazuyoshi
    Nakaoka, Hirofumi
    Yoshihara, Kosuke
    Adachi, Sosuke
    Kashima, Katsunori
    Tsuda, Hitoshi
    Moriya, Takuya
    Tanaka, Kenichi
    Enomoto, Takayuki
    Inoue, Ituro
    PLOS ONE, 2014, 9 (12):
  • [29] High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour
    O'Neill, C. J.
    McBride, H. A.
    Connolly, L. E.
    Deavers, M. T.
    Malpica, A.
    McCluggage, W. G.
    HISTOPATHOLOGY, 2007, 50 (06) : 773 - 779
  • [30] The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors
    Altman, Alon D.
    Nelson, Gregg S.
    Ghatage, Prafull
    McIntyre, John B.
    Capper, David
    Chu, Pamela
    Nation, Jill G.
    Karnezis, Anthony N.
    Han, Guangming
    Kalloger, Steve E.
    Koebel, Martin
    MODERN PATHOLOGY, 2013, 26 (09) : 1255 - 1263